Market revenue in 2023 | USD 13,967.8 million |
Market revenue in 2030 | USD 30,369.8 million |
Growth rate | 11.7% (CAGR from 2023 to 2030) |
Largest segment | Contract manufacturing |
Fastest growing segment | Contract Manufacturing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Contract Development, Contract Manufacturing |
Key market players worldwide | Catalent Inc, Lonza Group Ltd, Recipharm, Siegfried Holding AG, Thermo Fisher Scientific Inc, Labcorp Drug Development, Jabil Inc, Syngene, IQVIA Holdings Inc, Almac Group, Ajinomoto Co Inc, Alcami, Vetter Pharma-Fertigung |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to healthcare contract development and manufacturing organization market will help companies and investors design strategic landscapes.
Contract manufacturing was the largest segment with a revenue share of 77.99% in 2023. Horizon Databook has segmented the India healthcare contract development and manufacturing organization market based on contract development, contract manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
Low cost of labor, improvements in infrastructure, and easy availability of technical expertise are some of the major drivers of India’s healthcare CDMO market. Increase in government funding for R&D to accelerate new product development has made India one of the most favored locations for the establishment of manufacturing services.
Key market drivers include growth in demand for medical devices, increase in regulatory focus on quality control for manufacturing operations, and rapid uptake of local outsourcing services by global pharmaceutical companies. Supportive government reforms are anticipated to further boost the market in the country.
For instance, the Drug Technical Advisory Board (DTAB) agreed to grant a phase III clinical trial waivers to certain pharma drugs from the U.S. & EU markets. In 2019, the Indian government allowed 100% of foreign direct investments in the contract manufacturing sector. Such initiatives are anticipated to improve the cost effectiveness of contract manufacturing services in India.
Horizon Databook provides a detailed overview of country-level data and insights on the India healthcare contract development and manufacturing organization market , including forecasts for subscribers. This country databook contains high-level insights into India healthcare contract development and manufacturing organization market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account